LENSAR, Inc. (LNSR)
- Sector
- Healthcare
- Industry
- Medical Devices
- Last price
- $6.27
- As of
Kresmion compiles this page from LNSR's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
LENSAR, Inc. (LNSR): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-13.
See the full LNSR dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for LNSR on one page. Preview it with sample data, then open it live with a free account.
Preview the LNSR dossierActive signals for LNSR
- highCONSENSUS_BUY
3 tracked funds increased LNSR this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +96% to LNSR (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +97% to LNSR (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +860% to LNSR (2026Q2)
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 159.4%, EPS $0.10 vs $-0.1683 estimate
FREE, NO ACCOUNT
Every signal on LNSR, as it fires
You are seeing 5 of 11 signals recorded on LNSR since 2026-05-26.
The five above landed across 3 days. The other 6 were recorded on 3 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in LNSR (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 52634L108 · 2026Q2 | $689K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 52634L108 · 2026Q2 | $204K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, LNSR
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
LNSR against its peers
LNSR's operating margin of -47.6% ranks in the 52nd percentile of 23 Medical Devices sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-02-28.
| Metric | LNSR | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 51.7M USD | 32.0M USD | 65 | 23 |
| Gross margin | n/a | 50.6% | n/a | 19 |
| Operating margin | -47.6% | -55.8% | 52 | 23 |
| Net margin | -66.4% | -59.7% | 48 | 23 |
| Return on equity | n/a | -81.9% | n/a | 20 |
| 1 year | -47.6% | -29.4% | 39 | 21 |
Peers (23): HYPR, SERA, LUNG, ZOMDF, ECOR, OM, MYO, LUCD, APYX, MDNC, POSC, OWLT, MDAI, COCH, TELA, EBRCZ, SNWV, SRTS, XTNT, RPID, NNOX, STIM, QTRX. Left out: RTGN (no annual filing), TLTFF (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-02-28. Every figure is one full fiscal year read from one annual filing (LNSR: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow LNSR on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to LNSR for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.